An updated clinical guideline provides health care providers with practical advice on the treatment of seasonal allergic rhinitis (SAR).
published in the Annals of Allergy, Asthma and Immunology, provides recommendations on the best types and amounts of medications to treat SAR.
An updated clinical guideline offers health care providers with practical advice on the treatment of seasonal allergic rhinitis (SAR). The guidelines,
The guideline was developed by the Joint Task Force on Practice Parameters using a Grading of Recommendations, Assessment, Development, and Evaluations (GRADE) methodology. In the systematic review, the authors offered 3 key recommendations:
Additionally, the authors noted the importance of shared decision-making with patients, as well as encouraging health care providers to inform patients that taking 2 medications may not always be better than taking a single drug.
Although using a combination of an intranasal antihistamine and an intranasal corticosteroid dose often provides better relief than use of either medication by itself, the combination of the 2 types of drugs will likely be more expensive.
Health care providers should also make patients aware that using both medication, either combined or separately, may increase risk for adverse effects, according to the guidelines.
Reference
Dykewicz MS, Wallace DV, Baroody F, et al. Treatment of seasonal allergic rhinitis.
. 2017. Doi:
Annals of Allergy, Asthma & Immunologyhttp://dx.doi.org/10.1016/j.anai.2017.08.012
FDA Approves Rezafungin Injection for the Treatment of Candidemia, Invasive Candidiasis
March 27th 2023Rezafungin (Rezzayo; Cidara Therapeutics Inc, Melinta Therapeutics LLC) is the first new treatment option approved for individuals with candidemia and invasive candidiasis in more than a decade.